NDA 221443 · Gilead Sciences INC
Bixlenvo Sunlenca Starter Pack (Copackaged)
Bictegravir Sodium, Lenacapavir Sodium, Lenacapavir Sodium · Oral
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Aug 27, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
120
36 Phase 3, 12 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 29, 2026.
BIXLENVO SUNLENCA STARTER PACK is a co-packaged product containing BIXLENVO and SUNLENCA tablets and is indicated for the initiation of BIXLENVO, a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO [see Dosage and Administration (2.1) and Clinical Studies (14) ] . BIXLENVO SUNLENCA STARTER PACK is a co-packaged product containing BIXLENVO, a two-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) and lenacapavir (LEN), an HIV-1 capsid inhibitor; and SUNLENCA (lenacapavir) tablets, and is indicated for the initiation of BIXLENVO, a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO.
Mechanism: BIXLENVO is a fixed dose combination of the antiretroviral drugs bictegravir (BIC) and lenacapavir (LEN). SUNLENCA is the antiretroviral drug LEN [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) · BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM EQ 75MG BASE, EQ 50MG BASE; LENACAPAVIR SODIUM EQ 300MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bictegravir" as an intervention, any sponsor and status, largest first.
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07708727 · 700 participants (planned) · Start Jul 29, 2026 · Primary completion Oct 2030
Drug: GS-3242 Tablet; GS-3242 Injection and 3 more · For: HIV-1-infection
Sites: Torrance, California; New Haven, Connecticut; Ft. Pierce, Florida · 21 sites in all
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05502341 · 689 participants · Start Aug 16, 2022 · Primary completion Sep 29, 2025
Drug: Bictegravir; Lenacapavir and 2 more · For: HIV-1-infection
Sites: Berkeley, California; Beverly Hills, California; Los Angeles, California · 94 sites in all
ViiV HealthcareGSK (GSK)
NCT04542070 · 687 participants · Start Nov 9, 2020 · Primary completion Jul 13, 2022
Drug: Cabotegravir Tablets; Cabotegravir Injectable Suspension (CAB LA) and 3 more · For: HIV Infections
Sites: Bakersfield, California; Beverly Hills, California; Los Angeles, California · 117 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02607956 · 657 participants · Start Nov 11, 2015 · Primary completion May 12, 2017
Drug: DTG; F/TAF and 4 more · For: HIV-1 Infection
Sites: Phoenix, Arizona; Beverly Hills, California; Los Angeles, California · 125 sites in all
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04223791 · 643 participants · Start Feb 18, 2020 · Primary completion Aug 26, 2021
Drug: DOR/ISL; BIC/FTC/TAF and 2 more · For: HIV Infection
Sites: Phoenix, Arizona; Beverly Hills, California; Los Angeles, California · 89 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02607930 · 631 participants · Start Nov 13, 2015 · Primary completion May 9, 2017
Drug: ABC/DTG/3TC; B/F/TAF and 2 more · For: HIV-1 Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 121 sites in all
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06630286 · 609 participants · Start Oct 9, 2024 · Primary completion Apr 17, 2026
Drug: ISL/LEN; B/F/TAF and 2 more · For: HIV-1-infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 106 sites in all
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06630299 · 600 participants (planned) · Start Oct 8, 2024 · Primary completion Apr 23, 2026
Drug: ISL/LEN; Antiretroviral Combinations · For: HIV-1-Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, et al. · Lancet HIV 2023 · Randomized Controlled Trial, Multicenter Study
- Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study.
Ugarte A, De La Mora L, De Lazzari E, et al. · J Antimicrob Chemother 2024 · Clinical Trial, Research Support, Non-U.S. Gov't
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, et al. · Lancet HIV 2025 · Multicenter Study, Randomized Controlled Trial
- Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
Rockstroh JK, Ramgopal MN, Curran Fàbregas A, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV.
Sterman FL, Lalezari JP, Kowalczyk UM, et al. · AIDS 2023 · Clinical Trial, Research Support, Non-U.S. Gov't
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, et al. · Lancet HIV 2020 · Clinical Trial, Phase III, Comparative Study
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.